联环药业(600513.SH)：控股子公司药品通过仿制药一致性评价

Core Viewpoint - The company, Lianhuan Pharmaceutical (600513.SH), announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the supplemental application of Lincomycin Hydrochloride Injection, which has passed the consistency evaluation for generic drug quality and efficacy [1] Group 1 - The approved product, Lincomycin Hydrochloride Injection (specification: 2ml:0.6g), is classified as a lincosamide antibiotic and is clinically used for treating respiratory infections, skin and soft tissue infections, and bone and joint infections caused by sensitive bacteria [1] - The approval for the consistency evaluation is expected to help expand the market share of this drug and enhance its market competitiveness [1] - The receipt of the supplemental approval notification is not anticipated to have a significant impact on the company's recent operating performance [1]